When to Start LTOT in Chronic CO₂ Retention
LTOT should be started in patients with chronic CO₂ retention when they meet standard hypoxemia criteria (PaO₂ ≤7.3 kPa or ≤8 kPa with complications), but requires careful monitoring during titration and may necessitate concurrent nocturnal ventilatory support if CO₂ retention worsens. 1
Core Indication Criteria
The presence of chronic hypercapnia does not exclude patients from LTOT—in fact, LTOT should be ordered for patients with resting hypercapnia if they fulfill all other criteria for LTOT 1. The standard thresholds remain:
- PaO₂ ≤7.3 kPa (55 mmHg) with or without hypercapnia 2
- PaO₂ between 7.3-8.0 kPa (55-60 mmHg) if evidence of:
These measurements must be confirmed twice over at least a 3-week period during clinical stability 1.
Critical Management Algorithm for CO₂ Retainers
Step 1: Ensure Clinical Stability
Before assessment, patients must be:
- Clinically stable (not during acute exacerbation)
- On optimized medical therapy
- At least 3 weeks post-exacerbation 1
Step 2: Oxygen Titration with Intensive Monitoring
Patients with baseline hypercapnia require ABG monitoring after each flow rate titration 1. This is non-negotiable:
- Start at 1 L/min
- Titrate up in 1 L/min increments targeting SpO₂ >90%
- Perform ABG after each titration step to monitor for:
- Rising PaCO₂ (>1 kPa or 7.5 mmHg increase)
- Development of respiratory acidosis 1
Step 3: Decision Points Based on CO₂ Response
If respiratory acidosis and/or PaCO₂ rise >1 kPa (7.5 mmHg) develops:
First occurrence: This may indicate clinically unstable disease
- Optimize medical therapy further
- Reassess after 4 weeks 1
Recurs on repeat assessment (while apparently stable): Domiciliary oxygen should only be ordered in conjunction with nocturnal ventilatory support 1
This is a critical safety threshold—patients who consistently develop worsening hypercapnia with oxygen supplementation require NIV, not oxygen alone.
Common Pitfalls to Avoid
Do not reflexively withhold LTOT from CO₂ retainers. The evidence shows hypercapnia itself is not a contraindication 1. The key is the response to oxygen during titration, not the baseline CO₂ level.
Do not use oximetry alone for CO₂ retainers. While capillary blood gases or transcutaneous capnography can substitute for repeated ABGs during titration 1, some form of CO₂ monitoring is mandatory—oximetry cannot detect rising CO₂.
Do not increase flow rates during sleep in hypercapnic patients without reassessment. The BTS guideline specifically states that non-hypercapnic patients should increase flow by 1 L/min during sleep, but this recommendation does not apply to CO₂ retainers 1.
The NIV Consideration
For patients with neuromuscular disease, chest wall disorders, or COPD with persistent hypercapnia despite optimization, NIV should be the treatment of choice for type 2 respiratory failure, with LTOT added only if hypoxemia persists despite NIV 1. This represents a paradigm shift—oxygen is adjunctive to ventilatory support in these patients, not the primary therapy.
The GOLD 2017 guidelines note that NIV may be considered in selected patients with pronounced daytime hypercapnia and recent hospitalization 2, reinforcing that chronic CO₂ retention signals the need for ventilatory support consideration, not oxygen avoidance.
Practical Implementation
Target PaO₂ ≥8 kPa (60 mmHg) at rest after titration 1. Use for minimum 15 hours daily 1. Reassess at 3 months with repeat blood gases to confirm ongoing indication and ensure CO₂ has not worsened 1.